Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market Report 2024: Comprehensive Insights About 65+ Companies and 70+ Pipeline Drugs


Dublin, July 17, 2024 (GLOBE NEWSWIRE) -- The "Chronic Obstructive Pulmonary Disease - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.

This report provides comprehensive insights about 65+ companies and 70+ pipeline drugs in Chronic Obstructive Pulmonary Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Chronic Obstructive Pulmonary Disease- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Obstructive Pulmonary Disease pipeline landscape is provided which includes the disease overview and Chronic Obstructive Pulmonary Disease treatment guidelines.

The assessment part of the report embraces, in depth Chronic Obstructive Pulmonary Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Obstructive Pulmonary Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Obstructive Pulmonary Disease R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Obstructive Pulmonary Disease.

Chronic Obstructive Pulmonary Disease Emerging Drugs Chapters

This segment of the Chronic Obstructive Pulmonary Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic Obstructive Pulmonary Disease Emerging Drugs

Benralizumab: Astra ZenecaBenralizumab is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin-5 receptor (IL-5R) expressed on eosinophils and basophils. It inhibits the binding of IL-5 as well as the hetero-oligomerization of the alpha and beta subunits of the IL-5R, thus blocking, signal transduction. Besides, it is an afucosylated IgG, which gives it a high affinity for the Fc?RIIIa receptor in natural killer cells, macrophages, and neutrophils. In the TH2-high phenotype, IL-5 presents a central role as it is responsible for eosinophil differentiation, survival, activation, and migration to the lungs. The drug is currently in Phase III stage of its clinical trial evaluation to treatCOPD.

Dupilumab: Sanofi Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL) that induce inflammatory and immunological reactions in several atopic or allergic conditions, such as eczema, allergic reactions, and rhinosinusitis. Dupilumab was generated by recombinant DNA technology in Chinese Hamster Ovary cell suspension culture. Dupilumab is under investigation for its potential therapeutic use in chronic obstructive pulmonary disease and is currently in the Phase III stage ofdevelopment.

Tezepelumab: Amgen Tezepelumab (Tezspire) is a first-in-class human monoclonal antibody that works on the primary source of inflammation: the airway epithelium, which is the first point of contact for viruses, allergens, pollutants, and other environmental insults. Specifically, TEZSPIRE targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic, and other types of airway inflammation associated with severe asthma. TSLP is released in response to multiple triggers associated with asthma exacerbations, including allergens, viruses, and other airborne particles. Expression of TSLP is increased in the airways of patients with asthma and has been correlated with disease severity. Blocking TSLP may prevent the release of pro-inflammatory cytokines by immune cells, resulting in the prevention of asthma exacerbations and improved asthma control. Tezspire is being developed in collaboration with AstraZeneca and is currently being evaluated in Phase II to treat patients with chronic obstructive pulmonarydisease.

SNG001: Synairgen SNG001 boosts antiviral responses in the lungs, has a beneficial effect on lung function, and in more difficult to treat patients, improves asthma control during cold infections. The drug is currently being evaluated in the Phase II stage of development to treat patients withCOPD.

GSK3923868: Glaxo SmithKline GSK3923868, is a PI4k? inhibitor in development as a treatment for viral COPD exacerbations. It belongs to the class of antiasthmatics. The drug acts as a 1-phosphatidylinositol-4-kinase inhibitor. Currently, the drug is in Phase I of its clinical trial evaluation for the treatment of chronic obstructivepulmonarydisease.

Chronic Obstructive Pulmonary Disease: Therapeutic Assessment

This segment of the report provides insights about the different Chronic Obstructive Pulmonary Disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Chronic Obstructive Pulmonary Disease

There are approx. 65+ key companies which are developing the therapies for Chronic Obstructive Pulmonary Disease. The companies which have their Chronic Obstructive Pulmonary Disease drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca.

Key Questions

  • How many companies are developing Chronic Obstructive Pulmonary Disease drugs?
  • How many Chronic Obstructive Pulmonary Disease drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Obstructive Pulmonary Disease?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic Obstructive Pulmonary Disease therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Chronic Obstructive Pulmonary Disease and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Sanofi
  • AstraZeneca
  • Amgen
  • Synairgen
  • GlaxoSmithKline
  • Eisai
  • Meridigen Biotech
  • Chiesi
  • EmeraMed Limited
  • Verona Pharma
  • Tetherex Pharmaceuticals
  • Mereo BioPharma

Key Products

  • Lemborexant
  • UMC119-06
  • CHF5259
  • Emeramide
  • Ensifentrine
  • SNG001
  • GSK3923868
  • Benralizumab
  • Dupilumab
  • Tezepelumab
  • SelK2
  • BCT197

Phases

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

Route of Administration

  • Oral
  • Intravenous
  • Subcutaneous
  • Intramuscular

Molecule Type

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide

Chronic Obstructive Pulmonary Disease Report Insights

  • Chronic Obstructive Pulmonary Disease Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Chronic Obstructive Pulmonary Disease Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/5rkfzu

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

 

Contact Data